Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
ALMS vs CRMD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CRMD Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–3 Matrix Metrics)
CRMD Overall Winner
6-Pillar Tally: ALMS 2 – 4 CRMD
Matrix Metrics: ALMS 3 – 6 CRMD
As of Nov 17, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Alumis Inc. (ALMS) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ALMS carries a Unified Composite Score of 44.8/100 (HOLD) at $4.72 (N/M Forward P/E, -5938.1% operating margin), whereas CRMD carries 55.5/100 (HOLD) at $4.70 (29.5x Forward P/E, 41.0% operating margin).
- Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (55.5/100 HOLD vs. ALMS 44.8/100 HOLD) and 1.22β · 103% Vol risk profile, whereas ALMS leads top-line expansion (-7.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: ALMS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.1); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ALMS vs CRMD
ALMS
Alumis Inc. Common Stock
$4.72
-8.07% 1D
Market Cap
$727.0M
TTM Revenue
$7.2M
Forward P/E
N/M
Beta / 30D Vol
2.24β · 84% Vol
Unified Composite Score
44.8
HOLD
Tech 33.0
Fund 51.0
Flow 67.0
Mom 74.0
Weinstein Technical Phase
Markdown · Sell / avoid
CRMD
Head-to-Head Winner
CorMedix Inc.
$4.70
-2.59% 1D
Market Cap
$370.6M
TTM Revenue
$1.01B
Forward P/E
29.5x
Beta / 30D Vol
1.22β · 103% Vol
Unified Composite Score
55.5
HOLD
Tech 60.0
Fund 62.0
Flow 70.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (ALMS 2 – 4 CRMD)
1. Valuation Multiples
CRMD
Forward P/E
N/M
29.5x
Trailing P/E
N/M
2.4x
PEG Ratio
N/M
3.32x
EV / Revenue
96.7x
N/M
2. Growth & Scale
ALMS
Revenue Growth (YoY)
-7.7%
-47.7%
Earnings Growth (YoY)
+0.0%
+6.7%
TTM Revenue (USD)
$7.2M
$1.01B
Market Cap
$727.0M
$370.6M
3. Profitability & Quality
CRMD
Gross Margin
100.0%
87.4%
Operating Margin
-5938.1%
41.0%
Net Profit Margin
0.0%
15.5%
Return on Equity (ROE)
-110.9%
15.3%
4. Balance Sheet & Cash Flow
CRMD
Cash Generation (TTM)
-$352M
$755M
Cash Flow Margin
N/A
74.6%
Net Cash / Leverage
$27M Net Cash
$514M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ALMS
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
108.0% (11th %ile)
53.2% (22nd %ile)
Put/Call OI Skew
0.20x (Call-Skewed)
2.32x (Put-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
CRMD
OpEx & R&D Intensity
N/A
46.4% of Rev ($469M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
High-Margin Pricing Power Moat
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ALMS (3) vs CRMD (6)| Institutional Metric | ALMS | CRMD | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $727.0M | $370.6M | ALMS | |
| Trailing P/E Ratio | N/M | 2.4x | CRMD | |
| Forward P/E Ratio | N/M | 29.5x | CRMD | |
| Revenue Growth (YoY) | -7.7% | -47.7% | ALMS | |
| Operating Margin (TTM) | -5938.1% | 41.0% | CRMD | |
| Net Profit Margin | 0.0% | 15.5% | CRMD | |
| Return on Equity (ROE) | -110.9% | 15.3% | CRMD | |
| 52-Week Range Position | 0% ($5–$31) | 1% ($5–$13) | Tie | |
| Beta / 30D Volatility | 2.24β · 84% Vol | 1.22β · 103% Vol | ALMS | |
| Unified Institutional Score | 44.8 / 100 (HOLD) | 55.5 / 100 (HOLD) | CRMD | |
| Trailing 12M Revenue (USD) | $7.2M | $1.01B | Scale | |
| Gross Profit Margin (TTM) | 100.0% | 87.4% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 96.7x EV/Rev | 3.32x PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$352M ($27M Net Cash) | $755M ($514M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ALMS +10.91 pp
3M Horizon
CRMD +35.41 pp
6M Horizon
CRMD +38.09 pp
1Y Horizon
ALMS +43.83 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ALMS Revenue | CRMD Revenue | ALMS Op. Margin | CRMD Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2017 | N/A | $0M | N/A | -9997.4% | CRMD |
| FY2018 | N/A | $0M | N/A | -6250.4% | CRMD |
| FY2019 | N/A | $0M | N/A | -7416.3% | CRMD |
| FY2020 | N/A | $0M | N/A | -11378.4% | CRMD |
| FY2021 | N/A | $0M | N/A | -15417.5% | CRMD |
| FY2022 | N/A | $0M | N/A | -46819.9% | CRMD |
| FY2024 | N/A | $40M | N/A | -51.4% | CRMD |
| FY2025 | $20M | $310M | -1886.9% | 48.2% | CRMD |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ALMS
BREAKDOWN
Current IV
108.0%
IV Percentile
11th %ile
Put/Call OI Skew
0.20x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact ALMS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CRMD
BREAKDOWN
Current IV
53.2%
IV Percentile
22nd %ile
Put/Call OI Skew
2.32x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact CRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ALMS Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CRMD Moat Profile
High-Margin Pricing Power Moat
Biotechnology Operator
OpEx & R&D Reinvestment
46.4% of Rev ($469M)
90D Engineering Disclosures
0 Published
Investor FAQ ALMS vs CRMD Key Questions & Quantitative Answers
As of Nov 17, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Alumis Inc. (ALMS) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ALMS carries a Unified Composite Score of 44.8/100 (HOLD) at $4.72 (N/M Forward P/E, -5938.1% operating margin), whereas CRMD carries 55.5/100 (HOLD) at $4.70 (29.5x Forward P/E, 41.0% operating margin). Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (55.5/100 HOLD vs. ALMS 44.8/100 HOLD) and 1.22β · 103% Vol risk profile, whereas ALMS leads top-line expansion (-7.7% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ALMS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.1); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ALMS leads the Growth & Scale pillar: ALMS posts -7.7% YoY revenue growth and +0.0% YoY earnings growth on $7.2M TTM revenue (100.0% gross margin, -5938.1% operating margin), compared with CRMD at -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.01B TTM revenue (87.4% gross margin, 41.0% operating margin). Across the 8-period historical trajectory (FY2017 to FY2025), ALMS cumulative revenue shifted N/A while CRMD shifted +675.0%. In operating R&D and SG&A reinvestment, ALMS deploys N/A (0 90-day corporate R&D disclosures) versus 46.4% of Rev ($469M) (0 disclosures) for CRMD.
CRMD screens cheaper on headline valuation multiples. ALMS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 96.7x EV/Revenue (unreported FCF margin), whereas CRMD trades at 29.5x Forward P/E, 2.4x Trailing P/E, 3.32x PEG, and N/M EV/Revenue (74.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ALMS (-110.9% ROE) versus CRMD (15.3% ROE) capital efficiency.
In options market volatility and institutional positioning, ALMS carries 108.0% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.20x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.24β · 84% Vol realized risk). By comparison, CRMD carries 53.2% implied volatility (22nd %ile, Compressed (<25th %ile)), a 2.32x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.22β · 103% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CRMD vs ALMS · Reverse Pair
ALMS vs ABVX
· Sector Peer
ALMS vs MBX
· Sector Peer
ALMS vs MLYS
· Sector Peer
CRMD vs VTVT
· Sector Peer
CRMD vs CAPR
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem